🇺🇸 FDA
Pipeline program

Revlimid 5 mg hard capsules, DEXAMETHASONE, DEXAMETHASONE , DARZALEX 1800 mg solution for injection, BORTEZOMIB , Revlimid 10 mg hard capsules, BORTEZOMIB, DEXAMETHASONE

APHP190205

Phase 2 small_molecule active

Quick answer

Revlimid 5 mg hard capsules, DEXAMETHASONE, DEXAMETHASONE , DARZALEX 1800 mg solution for injection, BORTEZOMIB , Revlimid 10 mg hard capsules, BORTEZOMIB, DEXAMETHASONE for PRIMARY PLASMA CELL LEUKEMIA: A PROSPECTIVE PHASE II STUDY INCORPORATING DARATUMUMAB TO CHEMOTHERAPY AND STEM CELL TRANSPLANTATION is a Phase 2 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Pari Pharma GmbH
Indication
PRIMARY PLASMA CELL LEUKEMIA: A PROSPECTIVE PHASE II STUDY INCORPORATING DARATUMUMAB TO CHEMOTHERAPY AND STEM CELL TRANSPLANTATION
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials